Public Genome Governance Accountability

Introduction

Public Genome Governance Accountability refers to the legal and ethical responsibility of governments, regulators, research institutions, healthcare providers, and biotechnology companies for decisions and activities involving genomic science. It applies to genome sequencing, genetic testing, genome editing, genomic data collection, and genetically modified organisms.

The concept is an emerging governance principle rather than a single codified doctrine. It draws upon constitutional rights, biomedical ethics, data-protection law, environmental regulation, and public-health principles. Its central purpose is to ensure that genomic technologies are developed and applied transparently, safely, and fairly, while protecting human dignity, privacy, autonomy, and public welfare.

Accountability means that institutions must explain their decisions, comply with legal standards, prevent foreseeable harm, and provide remedies when rights are violated. Scientific expertise or commercial innovation cannot, by itself, justify decisions that affect individuals or the public.

Legal and Constitutional Framework

In India, Article 21 protects life, personal liberty, dignity, and privacy. Article 14 requires equality and non-arbitrary state action. Article 19 may protect scientific research and expression, subject to constitutional restrictions. Articles 48A and 51A(g) support environmental protection.

Genome governance accountability requires:

Transparency: Regulatory decisions should be reasoned and explainable.

Informed consent: Individuals should understand the purpose, risks, and possible consequences of genetic procedures.

Privacy safeguards: Genomic data must be protected against unauthorized access, disclosure, or misuse.

Independent review: Research and clinical applications should undergo appropriate ethics and biosafety assessment.

Monitoring and remedies: Institutions should monitor risks, report adverse events, and provide appropriate corrective measures.

Public participation: Decisions with broad social or environmental consequences should include meaningful consultation.

Important Case Laws

1. Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1

The Supreme Court recognized privacy as a fundamental right, including informational privacy and personal autonomy. It held that interference with privacy must have a legal basis, a legitimate purpose, and satisfy proportionality.

Indian Kanoon

Relevance: Genomic information can disclose health risks, ancestry, and biological relationships. The judgment supports accountability for institutions that collect, store, process, or disclose genetic data without adequate legal safeguards.

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

The Supreme Court explained that valid medical consent must be voluntary and based on adequate information. Consent to one procedure does not automatically authorize a materially different procedure.

Relevance: Genetic testing and genome editing require clear disclosure of their purpose, risks, limitations, and possible consequences. Institutions may be held responsible where consent is inadequate or the procedure exceeds its authorized scope.

3. Suchita Srivastava v. Chandigarh Administration (2009) 9 SCC 1

The Court recognized reproductive autonomy as part of personal liberty under Article 21 and emphasized the importance of consent in reproductive decisions.

Relevance: Genome-related reproductive interventions must respect bodily autonomy and informed choice. This principle is particularly important where interventions may have long-term or heritable effects.

4. Gene Campaign v. Union of India (2024) 2024 INSC 545

The Supreme Court considered challenges concerning genetically modified mustard, DMH-11. The Bench agreed that regulatory decisions concerning genetically modified organisms are subject to judicial review. It directed the Union Government to formulate a national policy on GM crops through consultation with relevant stakeholders and to address expert conflicts of interest. The judges differed on the validity of the specific approval, which was referred for further consideration.

Indian Kanoon+1

Relevance: This case demonstrates that biotechnology regulators must be accountable for the quality of their decision-making, the adequacy of biosafety review, public consultation, and the integrity of expert participation.

Forms of Accountability

Administrative accountability: Regulators must follow statutory procedures, give reasons for decisions, and respond to complaints.

Institutional accountability: Research organizations should maintain ethics review, consent records, secure data systems, and adverse-event reporting.

Civil liability: Negligent testing, unauthorized disclosure, or harmful interventions may give rise to claims where the legal requirements for liability are met.

Judicial accountability: Courts may review state action and regulatory decisions for legality, arbitrariness, and rights violations.

Public accountability: Institutions should disclose relevant safety information and provide meaningful opportunities for public participation, while protecting legitimate confidential information.

Conclusion

Public Genome Governance Accountability seeks to ensure that genomic innovation remains subject to law, ethical standards, and public oversight. In India, the constitutional principles of privacy, dignity, autonomy, equality, and environmental protection provide a foundation for this framework.

The cases of Puttaswamy, Samira Kohli, Suchita Srivastava, and Gene Campaign offer relevant guidance on genetic privacy, consent, regulatory scrutiny, and public participation. Although these cases do not establish one unified genome-specific doctrine, they support a governance system in which institutions must explain their decisions, prevent foreseeable harm, and provide remedies for unlawful conduct.